JP2023514872A5 - - Google Patents

Info

Publication number
JP2023514872A5
JP2023514872A5 JP2022551553A JP2022551553A JP2023514872A5 JP 2023514872 A5 JP2023514872 A5 JP 2023514872A5 JP 2022551553 A JP2022551553 A JP 2022551553A JP 2022551553 A JP2022551553 A JP 2022551553A JP 2023514872 A5 JP2023514872 A5 JP 2023514872A5
Authority
JP
Japan
Prior art keywords
amino
dioxopiperidine
difluorobenzyl
indazole
benzamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022551553A
Other languages
English (en)
Japanese (ja)
Other versions
JP7692924B2 (ja
JP2023514872A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2021/078240 external-priority patent/WO2021170109A1/en
Publication of JP2023514872A publication Critical patent/JP2023514872A/ja
Publication of JP2023514872A5 publication Critical patent/JP2023514872A5/ja
Application granted granted Critical
Publication of JP7692924B2 publication Critical patent/JP7692924B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022551553A 2020-02-26 2021-02-26 トロポミオシン受容体キナーゼ(trk)分解化合物とその使用方法 Active JP7692924B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2020076748 2020-02-26
CNPCT/CN2020/076748 2020-02-26
PCT/CN2021/078240 WO2021170109A1 (en) 2020-02-26 2021-02-26 Tropomyosin receptor kinase (trk) degradation compounds and methods of use

Publications (3)

Publication Number Publication Date
JP2023514872A JP2023514872A (ja) 2023-04-11
JP2023514872A5 true JP2023514872A5 (enExample) 2024-03-04
JP7692924B2 JP7692924B2 (ja) 2025-06-16

Family

ID=77490737

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022551553A Active JP7692924B2 (ja) 2020-02-26 2021-02-26 トロポミオシン受容体キナーゼ(trk)分解化合物とその使用方法

Country Status (11)

Country Link
US (1) US12410171B2 (enExample)
EP (1) EP4110772A4 (enExample)
JP (1) JP7692924B2 (enExample)
KR (1) KR20230010070A (enExample)
CN (2) CN120058711A (enExample)
AU (1) AU2021225981A1 (enExample)
BR (1) BR112022016901A2 (enExample)
CA (1) CA3173262A1 (enExample)
IL (1) IL295799A (enExample)
MX (1) MX2022010465A (enExample)
WO (1) WO2021170109A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11969472B2 (en) 2018-08-22 2024-04-30 Cullgen (Shanghai), Inc. Tropomyosin receptor kinase (TRK) degradation compounds and methods of use
AU2019323446B2 (en) 2018-08-22 2025-01-30 Cullgen (Shanghai), Inc. Tropomyosin receptor kinase (TRK) degradation compounds and methods of use
JP7692924B2 (ja) 2020-02-26 2025-06-16 クルゲン(シャンハイ),インク. トロポミオシン受容体キナーゼ(trk)分解化合物とその使用方法
WO2021185291A1 (zh) * 2020-03-17 2021-09-23 南京明德新药研发有限公司 蛋白降解调节剂与其使用方法
JP7814386B2 (ja) * 2020-11-05 2026-02-16 クロノス バイオ インコーポレイテッド Cdk9活性を調節するための化合物および方法
WO2022161414A1 (zh) * 2021-01-26 2022-08-04 成都茵创园医药科技有限公司 芳香化合物、含其的药物组合物及其应用
AU2022271290A1 (en) 2021-05-07 2023-11-23 Kymera Therapeutics, Inc. Cdk2 degraders and uses thereof
CN115504963A (zh) * 2021-06-22 2022-12-23 苏州开拓药业股份有限公司 一种c-Myc蛋白降解剂
WO2023036175A1 (zh) * 2021-09-08 2023-03-16 南京明德新药研发有限公司 戊二酰亚胺类化合物与其应用
WO2023055952A1 (en) * 2021-09-29 2023-04-06 C4 Therapeutics, Inc. Neurotrophic tyrosine receptor kinase (ntrk) degrading compounds
KR20240110576A (ko) * 2021-10-22 2024-07-15 글루탁스 테라퓨틱스 (상하이) 씨오., 엘티디. Crbn e3 리가제 리간드 화합물, 리간드 화합물에 기초하여 개발된 단백질 분해제 및 이들의 응용
EP4180428A1 (en) * 2021-11-12 2023-05-17 Genzyme Corporation Crystalline imidazo[4,5-b]pyridine compound, pharmaceutical compositions, and their use in treating medical conditions
CA3240524A1 (en) * 2021-12-08 2023-06-15 Gluetacs Therapeutics (Shanghai) Co., Ltd. E3 ubiquitin ligase ligand compound, protein degrader developed based thereon and their applications
EP4455133A4 (en) * 2021-12-24 2026-04-15 Suzhou Kintor Pharmaceuticals Inc MULTI-PROTEIN DEGRADING AGENT WITH AN IMIDE SKELETON
CN116217578B (zh) * 2021-12-30 2026-02-24 清华大学 一类抑制mTOR同时降解GSPT1蛋白的双功能化合物
TW202333670A (zh) * 2022-01-04 2023-09-01 大陸商海思科醫藥集團股份有限公司 抑制並降解irak4的化合物及其藥物组合物和藥學上的應用
EP4480948A4 (en) * 2022-02-14 2025-06-11 Gluetacs Therapeutics (Shanghai) Co., Ltd. Compound based on a quinazoline-substituted glutarimide skeleton and use thereof
KR20250004694A (ko) * 2022-04-06 2025-01-08 클루젠 (상하이), 인크. 암 치료를 위한 조성물 및 방법
IL317668A (en) * 2022-06-16 2025-02-01 Prelude Therapeutics Inc KAT6-targeted compounds with a ubiquitin ligase-binding residue
WO2024027792A1 (en) * 2022-08-05 2024-02-08 Shenzhen Newdel Biotech Co., Ltd. Protein kinase degrading agent, medicament and use
CN117659020A (zh) * 2022-09-07 2024-03-08 苏州朗睿生物医药有限公司 一种咪唑并[1,2-b]哒嗪衍生物及其制备方法和用途
TW202444373A (zh) * 2023-01-13 2024-11-16 大陸商深圳市新樾生物科技有限公司 化合物1在治療或預防特應性皮炎中的應用
CN121843947A (zh) * 2023-09-21 2026-04-10 成都茵创园医药科技有限公司 Irak降解剂及其用途
WO2025070690A1 (ja) 2023-09-29 2025-04-03 第一三共株式会社 3-フェニルプロピルアミン誘導体
WO2025155827A1 (en) * 2024-01-18 2025-07-24 St. Jude Children's Research Hospital, Inc. Small-molecule modulators of lymphocyte-specific protein tyrosine kinase and casein kinase 1a
WO2026035999A1 (en) 2024-08-09 2026-02-12 Triana Biomedicines, Inc. Anaplastic lymphoma kinase (alk) degraders and uses thereof
CN119613482A (zh) * 2024-12-09 2025-03-14 中国药科大学 具有端氨基结构的化合物及其制备方法、药物组合物和应用

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6306663B1 (en) 1999-02-12 2001-10-23 Proteinex, Inc. Controlling protein levels in eucaryotic organisms
ES2434946T3 (es) 2005-08-31 2013-12-18 Celgene Corporation Compuestos de isoindol imida y composiciones que los comprenden y métodos para usarlo
US8299057B2 (en) 2007-07-20 2012-10-30 Nerviano Medical Sciences S.R.L. Substituted indazole derivatives active as kinase inhibitors
EP2300469B1 (en) 2008-05-13 2015-06-24 Novartis AG Fused nitrogen containing heterocycles and compositions thereof as kinase inhibitors
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
TWI619713B (zh) 2010-04-21 2018-04-01 普雷辛肯公司 用於激酶調節的化合物和方法及其適應症
EP2588129A4 (en) 2010-06-30 2014-07-09 Univ Brandeis ON SMALL MOLECULES TARGETED PROTEIN REMOVAL
WO2012037155A2 (en) 2010-09-13 2012-03-22 Gtx, Inc. Tyrosine kinase inhibitors
AU2011338615B2 (en) 2010-12-07 2017-07-27 Yale University Small-molecule hydrophobic tagging of fusion proteins and induced degradation of same
JP2015508414A (ja) 2012-01-12 2015-03-19 イエール ユニバーシティ E3ユビキチンリガーゼによる標的タンパク質および他のポリペプチドの分解増強のための化合物および方法
US20150119435A1 (en) 2012-05-11 2015-04-30 Yale University Compounds useful for promoting protein degradation and methods using same
US9758522B2 (en) 2012-10-19 2017-09-12 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
EP3097091A1 (en) 2014-01-24 2016-11-30 AbbVie Inc. 6-phenyl- or 6-(pyridin-3-yl)indazole derivatives and methods of use
WO2015143652A1 (en) 2014-03-26 2015-10-01 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF
US20180228907A1 (en) 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
CN119591582A (zh) 2014-04-14 2025-03-11 阿尔维纳斯运营股份有限公司 基于酰亚胺的蛋白水解调节剂和相关使用方法
US20160058872A1 (en) 2014-04-14 2016-03-03 Arvinas, Inc. Imide-based modulators of proteolysis and associated methods of use
WO2016096709A1 (en) * 2014-12-16 2016-06-23 Eudendron S.R.L. Heterocyclic derivatives modulating activity of certain protein kinases
US9694084B2 (en) 2014-12-23 2017-07-04 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
GB201504314D0 (en) 2015-03-13 2015-04-29 Univ Dundee Small molecules
JP7269731B2 (ja) 2015-03-18 2023-05-09 アルビナス・オペレーションズ・インコーポレイテッド 標的タンパク質の分解向上のための化合物および方法
GB201506871D0 (en) 2015-04-22 2015-06-03 Glaxosmithkline Ip Dev Ltd Novel compounds
AU2016275051A1 (en) 2015-06-10 2017-12-07 Epizyme, Inc. EZH2 inhibitors for treating lymphoma
CN105085620B (zh) 2015-06-25 2018-05-08 中山大学附属第一医院 一种靶向泛素化降解Smad3的化合物
CN108137507A (zh) 2015-07-10 2018-06-08 阿尔维纳斯股份有限公司 基于mdm2的蛋白水解调节剂和相关的使用方法
CA2988436A1 (en) 2015-07-13 2017-01-19 Arvinas, Inc. Alanine-based modulators of proteolysis and associated methods of use
EP3337476A4 (en) 2015-08-19 2019-09-04 Arvinas, Inc. Compounds and methods for the targeted degradation of bromodomain-containing proteins
AU2016349781A1 (en) 2015-11-02 2018-05-10 Yale University Proteolysis targeting chimera compounds and methods of preparing and using same
JP7037500B2 (ja) 2016-04-06 2022-03-16 ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン Mdm2タンパク質分解剤
AU2017246453A1 (en) 2016-04-06 2018-11-08 The Regents Of The University Of Michigan Monofunctional intermediates for ligand-dependent target protein degradation
AU2017250076B2 (en) 2016-04-12 2021-07-22 The Regents Of The University Of Michigan Bet protein degraders
EP3455219A4 (en) * 2016-05-10 2019-12-18 C4 Therapeutics, Inc. AMINE-RELATED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION
CN109562107A (zh) * 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的杂环降解决定子体
CN109641874A (zh) * 2016-05-10 2019-04-16 C4医药公司 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
WO2017201069A1 (en) 2016-05-18 2017-11-23 Biotheryx, Inc. Oxoindoline derivatives as protein function modulators
KR101825065B1 (ko) 2016-05-24 2018-02-05 한국화학연구원 Alk 단백질의 분해를 유도하는 약학적 조성물 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
GB201610156D0 (en) 2016-06-10 2016-07-27 Otsuka Pharma Co Ltd Cliptac compositions
CA3025806C (en) 2016-06-23 2023-04-04 Dana-Farber Cancer Institute, Inc. Degradation of bromodomain-containing protein 9 (brd9) by conjugation of brd9 inhibitors with e3 ligase ligand and methods of use
ES2857743T3 (es) 2016-09-13 2021-09-29 Univ Michigan Regents 1,4-diazepinas fusionadas como degradadores de proteína BET
LT3660004T (lt) 2016-10-11 2023-06-12 Arvinas Operations, Inc. Junginiai ir metodai, skirti tikslinei androgeno receptoriaus degradacijai
EP3535265A4 (en) 2016-11-01 2020-07-08 Arvinas, Inc. PROTACS TARGETING ON TAU PROTEIN AND RELATED METHODS FOR USE
CN106543185B (zh) 2016-11-10 2017-12-15 吉林大学 一种靶向泛素化降解plk1和brd4蛋白的化合物及其应用
WO2018089736A1 (en) 2016-11-10 2018-05-17 Dana-Farber Cancer Institute, Inc. Degradation of protein kinases by conjugation of protein kinase inhibitors with e3 ligase ligand and methods of use
AU2017382176A1 (en) 2016-12-21 2019-05-30 Biotheryx, Inc. Thienopyrrole derivatives for use in targeting proteins, compositions, methods, and uses thereof
EP3559006A4 (en) 2016-12-23 2021-03-03 Arvinas Operations, Inc. COMPOUNDS AND METHODS FOR TARGETED DEGRADATION OF F TAL LIVER KINASE POLYPEPTIDES
RU2019121527A (ru) 2016-12-23 2021-01-15 Эрвинэс Оперейшнс, Инк. Химерные молекулы, нацеливающиеся на протеолиз egfr, и связанные с ними способы применения
EP3558994A4 (en) 2016-12-23 2021-05-12 Arvinas Operations, Inc. COMPOUNDS AND METHODS FOR TARGETED DEGRADATION OF FAST ACCELERATED FIBROSARCOMA POLYPEPTIDES
US11191741B2 (en) 2016-12-24 2021-12-07 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
MX2019008934A (es) 2017-01-26 2019-11-05 Arvinas Operations Inc Moduladores de la proteolisis del receptor de estrogeno y métodos asociados de uso,.
EP3577109A4 (en) 2017-01-31 2020-11-18 Arvinas Operations, Inc. CEREMONY LIGANDS AND BIFUNCTIONAL COMPOUNDS CONTAINING THEM
US11261179B2 (en) 2017-04-14 2022-03-01 University Of Dundee Small molecules
CN108976278B (zh) 2017-06-05 2021-04-06 海创药业股份有限公司 一种嵌合分子及其制备和应用
US20180353501A1 (en) 2017-06-09 2018-12-13 Arvinas, Inc. Modulators of proteolysis and associated methods of use
EP3725771B1 (en) * 2017-12-13 2026-02-04 Shanghaitech University Alk protein degradation agent and anti-tumor application thereof
WO2020023549A1 (en) 2018-07-24 2020-01-30 January Therapeutics, Inc. Nanoparticle compositions
AU2019323446B2 (en) 2018-08-22 2025-01-30 Cullgen (Shanghai), Inc. Tropomyosin receptor kinase (TRK) degradation compounds and methods of use
US11969472B2 (en) 2018-08-22 2024-04-30 Cullgen (Shanghai), Inc. Tropomyosin receptor kinase (TRK) degradation compounds and methods of use
JP7692924B2 (ja) 2020-02-26 2025-06-16 クルゲン(シャンハイ),インク. トロポミオシン受容体キナーゼ(trk)分解化合物とその使用方法
WO2023055952A1 (en) 2021-09-29 2023-04-06 C4 Therapeutics, Inc. Neurotrophic tyrosine receptor kinase (ntrk) degrading compounds

Similar Documents

Publication Publication Date Title
IL295799A (en) Trophomyosin receptor kinase (trk) degradation compounds and methods of use
US9199979B2 (en) Thiazolylphenyl-benzenesulfonamido derivatives as kinase inhibitors
JP2014511869A5 (enExample)
JP2009526072A5 (enExample)
JP2021535104A5 (enExample)
JP2009541268A5 (enExample)
JP2015524472A5 (enExample)
JP2007519754A5 (enExample)
JP2020503299A5 (enExample)
JP2019505541A5 (enExample)
JP2014525444A5 (enExample)
JP2017502940A5 (enExample)
JP2011515462A5 (enExample)
JP2016526576A5 (enExample)
RU2010110640A (ru) Соединения и композиции 5-(4-(галогеналкокси)фенил)пиримидин-2-амина в качестве ингибиторов киназ
JP2009542721A5 (enExample)
JP2015531773A (ja) スルファモイル−アリールアミド及びb型肝炎の治療のための薬剤としてのその使用
JP2005526723A5 (enExample)
JP2013527202A5 (enExample)
JP2016534124A5 (enExample)
US20130096149A1 (en) Heteroaryl compounds and compositions as protein kinase inhibitors
RU2008135690A (ru) Соединения и композиции в качестве ингибиторов протеинкиназы
JP2005508923A5 (enExample)
JP2016540811A5 (enExample)
JP2019505594A5 (enExample)